Clinical Trial Update: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating Survodutide (BI 456906) for weight loss in people with overweight/obesity and type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Survodutide (BI456906)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Obesity, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED